Literature DB >> 21870756

[The platysma myocutaneous flap (PMF) for reconstruction of defects after extended parotidectomy].

C C Ciocan-Pendefunda1, Carmen Vicol, Eugenia Popescu, V V Costan.   

Abstract

UNLABELLED: In order to reestablish the facial symmetry after the tumor removal, we can use sternocleidomastoid muscle transposition, dermis-fat graft, superficial musculoaponeurotic system (SMAS) plication, temporoparietal fascia flaps, microvascular free flaps and the platysma muscle flap. The technic depends on the size of the defect.
MATERIAL AND METHODS: In this study we present our results of using a superiorly based platysma myocutaneous flap for reconstruction of defects after extended parotidectomy. The patients were treated for malign tumor of parotid gland which invaded the skin.
RESULTS: All flaps were readily harvested at the time of tumor resection. Only two patients presented venous congestion. No flap was lost. There was no morbidity of donor site. The cosmetic outcome was satisfactory. DISCUSSION: The platysma myocutaneous flap is an alternative to more complex reconstructive technics, such as free flap transfer, and gives a satisfactory cosmetic result.
CONCLUSIONS: The platysma myocutaneous flap is easy to harvest and has low donor site morbidity. The main disadvantage is represented by the vascularity problems.

Entities:  

Mesh:

Year:  2011        PMID: 21870756

Source DB:  PubMed          Journal:  Rev Med Chir Soc Med Nat Iasi        ISSN: 0048-7848


  2 in total

1.  Primary repair and reconstruction of tumor defects in parotid masseter region: a report of 58 cases.

Authors:  Yong-Cong Cai; Chun-Yan Shui; Chao Li; Rong-Hao Sun; Yu-Qiu Zhou; Wei Liu; Xu Wang; Dinfen Zeng; Jian Jiang; Guiquan Zhu; Wei Wang; Zhenghua Jiang; Zhenqi Tang
Journal:  Gland Surg       Date:  2019-08

2.  Submental versus platysma flap for the reconstruction of complex facial defects following resection of head and neck tumors.

Authors:  Jawad Safdar; Fa-Yu Liu; Yousuf Moosa; Zhong-Fei Xu; Zhen-Ning Li; Chang-Fu Sun
Journal:  Pak J Med Sci       Date:  2014-07       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.